Faruqi & Faruqi Appointed Sole Lead Counsel to Represent Caribou Biosciences Shareholders in Securities Class Action
Faruqi & Faruqi Appointed Sole Lead Counsel to Represent Caribou Biosciences Shareholders in Securities Class Action
On March 25, 2025, Honorable Vince Chhabria of the Northern District of California appointed Faruqi & Faruqi, LLP, as sole lead counsel in Saylor v. Caribou Biosciences, Inc. et al, Docket No. 3:24-cv-09413 (N.D. Cal. Dec 24, 2024). The Caribou Biosciences, Inc. class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) they had overstated CB-010’s safety, efficacy, and durability relative to approved autologous CAR-T cell therapies in treating patients with r/r B-NHL and/or LBCL, as well as CB-010’s overall clinical results and commercial prospects; (ii) Caribou was at significant risk of having insufficient cash, liquidity, and/or other capital to fund its current business operations, including preclinical research activities associated with the allogeneic CAR-NK platform; and (iii) all the foregoing was likely to have a significant negative impact on Caribou’s business and operations.
For further inquiries regarding this matter, please contact James M. Wilson, Jr. at jwilson@faruqilaw.com or (212) 983-9330.
A copy of the Court’s order is linked below.
Documents:
